| abstract |
The present art provides triazolopyridine-3-one or a pharmaceutically acceptable salt thereof, a method for preparing them, a pharmaceutical composition containing them, and their use. Triazolopyridin-3-one or pharmaceutically acceptable salts thereof exhibit inhibitory activity against VAP-1 and are therefore useful, for example, for the treatment and prevention of nonalcoholic steatohepatitis (NASH). Can be applied. We have found that triazolopyridine-3-one with 3-fluoroallylamine or 3,3-difluoroallylamine groups or pharmaceutically acceptable salts thereof exhibit inhibitory activity on VAP-1. rice field. Therefore, triazolopyridine-3-one or salts thereof can be usefully used in the treatment and prevention of various VAP-1-mediated diseases such as nonalcoholic steatohepatitis (NASH). |